• 1
    Abou-Assi S, Vlahcevic ZR. Hepatic encephalopathy: metabolic consequence of cirrhosis often is reversible. Postgrad Med 2001; 109: 5270.
  • 2
    Blei AT, Córdoba J, for the Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am J Gastroenterol 2001; 96: 196876.
    Direct Link:
  • 3
    Bass NM, Ahmed A, Johnson L, Gardner JD. Rifaximin treatment is beneficial for mild hepatic encephalopathy. Hepatology 2004; 40: 646A (abstract).
  • 4
    The Burden of Gastrointestinal Diseases. Bethesda, Maryland: American Gastroenterological Association; 2001; 412.
  • 5
    Lewis M, Howdle PD. The neurology of liver failure. Q J Med 2003; 96: 62333.
  • 6
    Bustamante J, Rimola A, Ventura P-J, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol 1999; 30: 8905.
  • 7
    Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997; 337: 4739.
  • 8
    Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. Gastroenterology 1977; 72: 57383.
  • 9
    Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis 1978; 23: 398406.
  • 10
    Camma C, Fiorello F, Tine F, Marchesini G, Fabbri A, Pagliaro L. Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis. Dig Dis Sci 1993; 38: 91622.
  • 11
    Bircher J, Muller J, Guggenheim P, Haemmerli UP. Treatment of chronic portal-systemic encephalopathy with lactulose. Lancet 1966; 1: 8902.
  • 12
    Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004; 328: 104651.
  • 13
    Strauss E, Tramote R, Silva EPS, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 1992; 39: 5425.
  • 14
    Blanc P, Daures JP, Liautard J, et al. Lactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial [in French]. Gastroenterol Clin Biol 1994; 18: 10638.
  • 15
    Morgan MH, Read AE, Speller DCE. Treatment of hepatic encephalopathy with metronidazole. Gut 1982; 23: 17.
  • 16
    Hawkins RA, Jessy J, Mans AM, Chedid A, DeJoseph MR. Neomycin reduces the intestinal production of ammonia from glutamine. Adv Exp Med Biol 1994; 368: 12534.
  • 17
    Green PHR, Tall AR. Drugs, alcohol and malabsorption. Am J Med 1979; 67: 106676.
  • 18
    Loft S, Sonne J, Døssing M, Andreasen PB. Metronidazole pharmacokinetics in patients with hepatic encephalopathy. Scand J Gastroenterol 1987; 22: 11723.
  • 19
    Jiang Z-D, Ke S, Palazzini E, Riopel L, DuPont H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000; 44: 22056.
  • 20
    Xifaxan [package insert]. Morrisville, NC: Salix Pharmaceuticals, Inc; 2005.
  • 21
    Pakyz AL. Rifaximin: a new treatment for travelers’ diarrhea. Ann Pharmacother 2005; 39: 2849.
  • 22
    Huang DB, DuPont HL. Rifaximin – a novel antimicrobial for enteric infections. J Infect 2005; 50: 97106.
  • 23
    Festi D, Mazzella G, Orsini M, et al. Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res 1993; 54: 598608.
  • 24
    Williams R, James OFW, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000; 12: 2038.
  • 25
    Puxeddu A, Quartini M, Massimetti A, Ferrieri A. Rifaximin in the treatment of chronic hepatic encephalopathy. Curr Med Res Opin 1995; 13: 27481.
  • 26
    Mas A, Rodés J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003; 38: 518.
  • 27
    Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993; 13: 10918.
  • 28
    Massa P, Vallerino E, Dodero M. Treatment of hepatic encephalopathy with rifaximin: double blind, double dummy study versus lactulose. Eur J Clin Res 1993; 4: 718.
  • 29
    Giacomo F, Francesco A, Michele N, Oronzo S, Antonella F. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res 1993; 4: 5766.
  • 30
    Pedretti G, Calzetti C, Missale G, Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991; 23: 1758.
  • 31
    Di Piazza S, Filippazzo MG, Valenza LM, et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 1991; 23: 4037.
  • 32
    Miglio F, Valpiani D, Rossellini SR, Ferrieri A. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. Curr Med Res Opin 1997; 13: 593601.
  • 33
    Testa R, Eftimiadi C, Sukkar GS, et al. A non-absorbable rifamycin for treatment of hepatic encephalopathy. Drugs Exp Clin Res 1985; 11: 38792.
  • 34
    De Marco F, Amato PS, D'Arienzo A. Rifaximin in collateral treatment of portal-systemic encephalopathy: a preliminary report. Curr Ther Res Clin Exp 1984; 36: 66874.
  • 35
    Parini P, Cipolla A, Ronchi M, Salzetta A, Mazzella G, Roda E. Effect of rifaximin and paromomycin in the treatment of portal-systemic encephalopathy. Curr Ther Res Clin Exp 1992; 52: 349.
  • 36
    Sama C, Morselli-Labate AM, Pianta P, Lambertini L, Berardi S, Martini G. Clinical effects of rifaximin in patients with hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: an open-label pilot study. Curr Ther Res Clin Exp 2004; 65: 41322.
  • 37
    Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vecchio  Blanco C. Cyclic treatment of chronic hepatic encephalopathy with rifaximin: results of a double-blind clinical study. Minerva Gastroenterol Dietol 2003; 49: 5362.
  • 38
    Lata J, Hulek P, Spicak J, et al. Safety and efficacy of rifaximin in the treatment of hepatic encephalopathy in liver cirrhosis. Hepatology 2002; 36: 519A (abstract).
  • 39
    Paik Y-H, Lee KS, Han K-H, et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 2005; 46: 399407.
  • 40
    Leevy CB. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci (in press).
  • 41
    Spiegel BM, Huang E, Esrailian E. Is rifaximin cost-effective in the management of hepatic encephalopathy?. Gastroenterology 2006; 130(Suppl. 2): A-806 Presented at Digestive Disease Week, Los Angeles, CA, May 20–25, 2006.
  • 42
    Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 1992; 16: 13844.
  • 43
    Morgan MY. Branched chain amino acids in the management of chronic liver disease. Facts and fantasies. J Hepatol 1990; 11: 13341.
  • 44
    James JH, Ziparo V, Jeppsson B, Fischer JE. Hyperammonaemia, plasma aminoacid imbalance, and blood-brain aminoacid transport: a unified theory of portal-systemic encephalopathy. Lancet 1979; 2: 7725.
  • 45
    Chalasani N, Gitlin N. Severe recurrent hepatic encephalopathy that responded to oral branched chain amino acids. Am J Gastroenterol 1996; 91: 12668.
  • 46
    Horst D, Grace ND, Conn HO, et al. Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial. Hepatology 1984; 4: 27987.
  • 47
    Naylor CD, O'Rourke K, Detsky AS, Baker JP. Parenteral nutrition with branched-chain amino acids in hepatic encephalopathy. A meta-analysis. Gastroenterology 1989; 97: 103342.
  • 48
    Fabbri A, Magrini N, Bianchi G, Zoli M, Marchesini G. Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy. JPEN J Parenter Enteral Nutr 1996; 20: 15964.
  • 49
    Uribe M, Farca A, Marquez MA, Garcia-Ramos G, Guevara L. Treatment of chronic portal systemic encephalopathy with bromocriptine: a double-blind controlled trial. Gastroenterology 1979; 76: 134751.
  • 50
    Barbaro G, Di Lorenzo G, Soldini M, et al. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology 1998; 28: 3748.
  • 51
    Kircheis G, Nilius R, Held C, et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997; 25: 135160.
  • 52
    Stauch S, Kircheis G, Adler G, et al. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998; 28: 85664.
  • 53
    Levocarnitine [package insert]. Bedford, Ohio: Bedford Laboratories; 2004.
  • 54
    Malaguarnera M, Pistone G, Elvira R, et al. Effects of L-carnitine in patients with hepatic encephalopathy. World J Gastroenterol 2005; 11: 7197202.
  • 55
    Del Olmo JA, Castillo M, Rodrigo JM, et al. Effect of L-carnitine upon ammonia tolerance test in cirrhotic patients. Adv Exp Med Biol 1990; 272: 197208.
  • 56
    Gentile S, Guarino G, Romano M, et al. A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol 2005; 3: 184191.